(Reuters) – The U.S. Food and Drug Administration said on Tuesday it will now review only a small number of emergency use authorization requests for COVID tests that are likely to have a significant benefit to public health, including fulfilling an unmet need. The agency is revising its COVID-19 test policy in light of the current manufacturing status and number of cases, it said, adding companies seeking EUA for their COVID tests will have to now apply for the agency’s traditional premarket review process. “Taking into account the current status of manufacturing capacity and consumer access…..